
    
      Randomized, parallel-arm, active control, multi-center study assessing the safety of Dextenza
      for the treatment of ocular pain and inflammation following surgery for pediatric cataract.
      The subjects will be followed for approximately 2-3 months from screening to the last visit.
    
  